POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.482
https://www.valueinhealthjournal.com/article/S1098-3015(21)02277-4/fulltext
Section Title :
Section Order :
10017
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02277-4&doi=10.1016/j.jval.2021.11.482